Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMC84Y9)

• Drug Name: Tepoditamab Drug Info
• Synonyms: MCLA-117

Indication

Disease Entry	ICD 11	Status	REF
Acute myelogenous leukaemia	2A41	Phase 1	[1]

• Cross-matching ID: TTD Drug ID: DMC84Y9

Molecule-Related Drug Atlas

Drug(s) Targeting T-cell surface glycoprotein CD3 (CD3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Blinatumomab	DMGECIJ	Acute lymphoblastic leukaemia	2A85	Approved	[3]
Mosunetuzumab	DM15ZIB	Follicular lymphoma	2A80	Approved	[4]
Epcoritamab	DMEX86V	Diffuse large B-cell lymphoma	2A81	Approved	[5]
Talquetamab	DMXRENI	Multiple myeloma	2A83	Approved	[6]
Elranatamab	DMG1MW2	Multiple myeloma	2A83	Approved	[7]
Nivatrotamab	DMAOUZV	Small-cell lung cancer	2C25.Y	Phase 2	[8]
Otelixizumab	DMFNDBC	Type-1 diabetes	5A10	Phase 2	[9]
Plamotamab	DMOV28A	Diffuse large B-cell lymphoma	2A81	Phase 2	[10]
Odronextamab	DMP6NVV	B-cell non-hodgkin lymphoma	2B33.5	Phase 2	[11]
Tarlatamab	DME33OU	Small-cell lung cancer	2C25.Y	Phase 2	[12]

Drug(s) Targeting Myeloid inhibitory C-type lectin-like receptor (CD371)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
CD123/CLL1 CAR-T Cells	DM45Z3P	Acute myeloid leukaemia	2A60	Phase 2/3	[13]
CLL1 CAR-T Cell	DMUOMBZ	Acute myeloid leukaemia	2A60	Phase 2/3	[13]
CLL1-specific gene-engineered T cells	DMCT917	Acute myeloid leukaemia	2A60	Phase 1/2	[14]
CAR-T cells targeting CLL1	DMCPM92	leukaemia	2A60-2B33	Phase 1/2	[15]
CLL1-CD33 cCART cell therapy	DM5EM04	Acute myeloid leukaemia	2A60	Phase 1	[16]
CLT030	DM674MP	Acute myeloid leukaemia	2A60	Phase 1	[17]
KITE-222	DMPF49Z	Acute myeloid leukaemia	2A60	Phase 1	[18]
UCART-CLL1	DMT06MI	Multiple myeloma	2A83	Preclinical	[19]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Myeloid inhibitory C-type lectin-like receptor (CD371)	TT70N8V	CL12A_HUMAN	Not Available	[2]
T-cell surface glycoprotein CD3 (CD3)	TTUN7MC	NOUNIPROTAC	Not Available	[2]

References

• [1] ClinicalTrials.gov (NCT03038230) MCLA-117 in Acute Myelogenous Leukemia. U.S. National Institutes of Health.
• [2] MCLA-117, a CLEC12AxCD3 bispecific antibody targeting a leukaemic stem cell antigen, induces T cell-mediated AML blast lysis. Expert Opin Biol Ther. 2019 Jul;19(7):721-733.
• [3] 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
• [4] Mitigating the risk of cytokine release syndrome in a Phase I trial of CD20/CD3 bispecific antibody mosunetuzumab in NHL: impact of translational system modeling. NPJ Syst Biol Appl. 2020 Aug 28;6(1):28.
• [5] Clinical pipeline report, company report or official report of Genmab.
• [6] FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 761342
• [7] FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 761345
• [8] Clinical pipeline report, company report or official report of Y-mAbs Therapeutics.
• [9] Low-dose otelixizumab anti-CD3 monoclonal antibody DEFEND-1 study: results of the randomized phase III study in recent-onset human type 1 diabetes.Diabetes Care.2014 Oct;37(10):2746-54.
• [10] Plamotamab (XmAb(?)13676) for Ibrutinib- refractory CXCR4-mutated extramedullary Waldenstr?m macroglobulinemia. Leuk Lymphoma. 2022 Mar;63(3):738-742.
• [11] Odronextamab, a human CD20*CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial. Lancet Haematol. 2022 May;9(5):e327-e339.
• [12] Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study. J Clin Oncol. 2023 Jun 1;41(16):2893-2903.
• [13] ClinicalTrials.gov (NCT03631576) CD123/CLL1 CAR-T Cells for R/R AML
• [14] ClinicalTrials.gov (NCT03222674) Multi-CAR T Cell Therapy for Acute Myeloid Leukemia
• [15] ClinicalTrials.gov (NCT03312205) CAR-T Cells for Relapsed or Refractory Haematopoietic and Lymphoid Malignancies
• [16] Clinical pipeline report, company report or official report of iCell Gene Therapeutics.
• [17] Clinical pipeline report, company report or official report of Cellerant Therapeutics.
• [18] Clinical pipeline report, company report or official report of Gilead
• [19] Off-the-shelf' allogeneic CAR T cells: development and challenges. Nat Rev Drug Discov. 2020 Mar;19(3):185-199.